PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab in Reversing Antiplatelet Activity of Ticagrelor

PhaseBio announced topline data from its Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old. The multi-center, randomized, double-blind, placebo-controlled study enrolled 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of ticagrelor and low-dose aspirin. The Phase 2b pivotal trial was conducted concurrently with the company’s ongoing REVERSE-IT Phase 3 pivotal trial of bentracimab.

The trial achieved its primary endpoint, reversal of ticagrelor’s inhibition of platelet function in actively treated subjects versus placebo as measured using the point-of-care VerifyNow PRUTest platelet function assay (VerifyNow).

A prespecified interim analysis from the REVERSE-IT trial will be presented on Monday, November 15, 2021, during a late-breaking science session at the American Heart Association’s Scientific Sessions 2021. The Company is commencing preparation of a Biologics License Application (BLA) and, pending results of REVERSE-IT, is targeting a BLA submission to the FDA in mid-2022.

About Bentracimab

Bentracimab is a novel, reco...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee